Technovalia announces that its strategic partner BioNet has published in Vaccines the results of the phase 2 trial evaluating PTgen-containing vaccines in women of childbearing age (WOCBA).

In collaboration with PATH and financial support from the Bill & Melinda Gates Foundation, a phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis toxin (PTgen) was conducted in women of childbearing age in Thailand to identify formulations to advance to a trial in pregnant women.

Conclusions: All recombinant acellular pertussis vaccines were safe and immunogenic in women of childbearing age, and all met pre-defined immunogenicity criteria to advance to a trial in pregnant women.

Source: https://pubmed.ncbi.nlm.nih.gov/34789403/

BioNet’s PTgen-containing vaccine Pertagen^® is currently being tested in the Pertaprime study, a phase 2/3 trial in healthy adults aged 18 – 25 years old in Western Australia.

For more information, please visit https://technovalia.com/research/31-pertaprime-study-recruitment or email This email address is being protected from spambots. You need JavaScript enabled to view it.